FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Federal Register

Guide on Gene Therapies for Retinal Disorders

Federal Register notice: FDA makes available a draft guidance entitled Human Gene Therapy for Retinal Disorders; Draft Guidance for Industry.

New, Updated FDA Gene Therapy Guidances

FDA releases three new and three updated guidances to help sponsors developed gene therapy products, including for specific diseases.

Federal Register

Comments Sought on Formal PDUFA Meeting Guide

Federal Register notice: FDA seeks comments on an information collection extension for its Guidance on Formal Meetings With Sponsors and Applicants fo...

Federal Register

Draft Guide on Smallpox Antiviral Development

Federal Register notice: FDA makes available a draft guidance entitled Smallpox (Variola Virus) Infection: Developing Drugs for Treatment or Preventio...

Marketing

Materials Promote Unapproved Arog Drug: OPDP

CDERs Office of Prescription Drug Promotion says an Arog exhibit booth and Web page are promoting its investigational unapproved new drug Crenolanib.

Medical Devices

Medtronic Gains OK for Easier HVAD Device Implantation

FDA approves a Medtronic PMA for a less-invasive implant approach for its HVAD System, a left ventricular assist device for patients with advanced hea...

DoJ Launches Fraud Task Force

The Justice Department establishes a Task Force on Market Integrity and Consumer Fraud to step up efforts against healthcare and other types of fraud.

Biologics

Priority Review for Keytruda in Hepatocellular Carcinoma Patients

FDA accepts for priority review a Merck supplemental BLA for Keytruda (pembrolizumab), an anti-PD-1 therapy for treating previously treated patients w...

Medical Devices

Zebra Medical Coronary Calcium Algorithm Cleared

FDA clears a Zebra Medical Vision 510(k) for its Coronary Calcium Scoring algorithm for automatically calculating a patients Agatston equivalent coron...

Human Drugs

Company Comments on Therapeutic Protein Interactions

Four drug companies offer general and specific comments on the FDA framework for assessing drug-drug interactions for therapeutic proteins.